Neurotech selects Cencora to support the US launch of its cell therapy

(Image credit: AdobeStock/ronnarong)

Neurotech Pharmaceuticals, Inc., has selected Cencora to provide integrated distribution and commercialization services to support the launch of Neurotech’s cell therapy in the United States.¹

The US Food and Drug Administration (FDA) approved revakinagene taroretcel-lwey (ENCELTO) from Neurotech Pharmaceuticals for the treatment of Macular Telangiectasia type 2 (MacTel) on March 6, 2025. At the date of approval, ENCELTO is the first and only FDA-approved Treatment for MacTel.²

According to the press release,¹ Cencora will serve as the exclusive specialty distributor and provide comprehensive commercialization support, including third-party logistics, specialty logistics and patient support services. Cencora will leverage its Integration Hub solution to orchestrate services and provide healthcare providers and patient services teams enhanced visibility across the treatment journey, helping to simplify the care coordination process and streamline the patient journey.

Kevin Chinn, Vice President, Cell & Gene Therapy at Cencora remarked on this partnership, saying, “We believe in the promise of cell and gene therapies and are committed to providing CGT developers with integrated support tailored to their needs to help accelerate speed-to-market and support product success. Through this partnership with Neurotech, we’ll leverage our distribution infrastructure and commercialization services to help streamline market entry, reduce potential access barriers and support secure storage and distribution, enabling efficient access to the product.”

ENCELTO is expected to be available in the United States for patients starting in June 2025.²

Reference:

1. Cencora to Support Commercial Launch of Neurotech’s Encapsulated Cell Therapy in the United States. Cencora. April 28, 2025. Accessed April 28, 2025. https://www.cencora.com/newsroom/cencora-to-support-commercial-launch-of-neurotechs-encapsulated-cell-therapy-in-the-united-states

2. Neurotech’s ENCELTO(TM) (revakinagene taroretcel-lwey) Approved by the FDA for the Treatment of Macular Telangiectasia Type 2 (MacTel). Press release. Neurotech Pharmaceuticals. Published March 6, 2025. Accessed March 6, 2025. https://www.neurotechpharmaceuticals.com/neurotechs-enceltotm-revakinagene-taroretcel-lwey-approved-by-the-fda-for-the-treatment-of-macular-telangiectasia-type-2-mactel/